pegaspargase
idelalisib
thioguanine
ponatinib
alvocidib
asparaginase
Elspar
axicabtagene ciloleucel
venetoclax
tafasitamab
fludarabine
acalabrutinib
antileukemia
antileukemic
antilymphocyte
lymphangiostatic
chlorambucil
alemtuzumab
Leukeran
chloraminophene
acute lymphoblastic leukemia
axicabtagene
tyrosine kinase inhibitor
antileprotic
lymphagogue
506U78
mogamulizumab
antilymphangiogenic
lymphocytotoxic
promyeloleukemia
immunocyte
EPOCH
leucocrit
ofatumumab
pirtobrutinib
rituximab
homoharringtonine
autolymphocyte
lysocyte
olutasidenib
lymphoblastoid
ubenimex
hybridoma
leukotoxigenic
acedapsone
clofarabine
afutuzumab
lumiliximab
antileukotriene
prolymphangiogenic
galiximab
lymphographical
lymphosuppressive
leukotoxin
tazemetostat
sialophorin
lymphohyperplasia
achroacytosis
lymphotoxin
immunotherapeutic
gemtuzumab ozogamicin
leukocytoid
leukoblastic
lymphosuppression
lymphoblastic leukemia
lymphodeplete
lymphocytoma
erythroleukemia
antileukoprotease
antileukocidin
loncastuximab tesirine
leucoblastoma
lenzilumab
umbralisib
thiotepa
ibritumomab tiuxetan
lymphoepithelium
acasunlimab
Waldenström's macroglobulinemia
hematogone
piposulfan
DLBCL
leukaemogenesis
talacotuzumab
lymphoplasmocytic
lymphocytolytic
Castleman's disease
resminostat
leukolysis
ivosidenib
leukemogenicity
lympho-
biochemotherapy
monalizumab
mosunetuzumab
chemoagent
dapsone
nonlymphopenic